Dr. Michael J. Horwath

Nicholas Argento, M.D. attended Georgetown University and graduated Magna Cum Laude with a BS in Biology, then the University of Maryland School of Medicine and graduated Cum Laude. He completed his residency in Internal Medicine and fellowship in Diabetes, Endocrine and Metabolism at the University of Maryland Medical System. He joined Maryland Endocrine full time in 1991. He has been the Medical Advisor to the diabetes program at Johns Hopkins Howard County Medical Center since 1995, and gives talks regularly to medical and patient audiences on diabetes. He has a strong interest in type 1 diabetes (T1D), and has extensive experience in utilizing insulin pumps and continuous glucose monitoring (CGM) to help patients safely achieve better blood glucose control. He has 4 publications in medical journals on different aspects of CGM use, and was co-author or contributor to multiple chapters in the 2013 American Diabetes Association book, Putting Your Patient On The Pump, 2nd edition. He has presented clinical research multiple times at the American Diabetes Association Scientific Sessions and other medical meetings, and has spoken to local, national, and international audiences on insulin pumps and the clinical application of CGM technology. He is very active on and lends medical support to and has written numerous articles for the T1DExchange website myglu.org, a website dedicated to outreach, research and engagement of and for the T1D community. For more information, visit marylandendocrine.com. Dr. Argento is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Hypothyroidism, Type 2 Diabetes (T2D), and Vitamin D Deficiency.

Robert Vigersky is an Endocrinologist in Bethesda, Maryland. Dr. Vigersky is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Low Blood Sugar, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

Dr. Donner's clinical and research interests have focused on the prevention of complications in patients with type 1 and 2 diabetes. For 6 years, he was the Associate Medical Director of the Joslin Diabetes Center affiliate at the University of Maryland, and then Medical Director from 2004 - 2010. After joining the faculty at Johns Hopkins University in 2010, his clinical and research interests became fully dedicated to diabetes. He became the Director of The Johns Hopkins Diabetes Center in 2011. He has been a clinical investigator in a number of NIH- and industry-funded diabetes research trials. Dr. Donner was a co-PI in the NIH-funded Veterans Affairs Implantable Insulin Pump Study, a Co-PI on the NIDDK-funded Diabetes Control and Complications Trial / Epidemiology of Diabetes Intervention and Complications (DCCT / EDIC) Study for 16 years, and Co-PI for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) for 7 years. Recently, he has served as PI for the Durable-response therapy Evaluation For Early or New-onset type 1 Diabetes (DEFEND-1). Dr. Donner is currently collaborating with Dr. Abdel Hamad in Immunology on preventing B-regulatory cell apoptosis using a novel monoclonal antibody targeting the presumptive apoptotic factor. This antibody prevents the development of type 1 diabetes in non obese diabetic mice. Dr. Donner is the PI for Johns Hopkins for TrialNet, a multicenter, international consortium of investigators studying ways to prevent Type 1 diabetes and preserve insulin secretion in individuals with newly diagnosed Type 1 diabetes. He is also a PI for a study investigating FIAsp, a faster-acting insulin aspart in subjects with type 1 diabetes, and is working with investigators at the Johns Hopkins School of Engineering on an implantable insulin pump which delivers insulin intravenously. Dr. Donner is rated as an Advanced provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Diabetic Nephropathy, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.